VICTORIA, Seychelles, April 9, 2025 /PRNewswire/ -- MEXC, a leading global cryptocurrency exchange, has launched an exclusive BTC Fixed Saving Event offering an Annual Percentage Rate (APR) of up to 99%, in anticipation of the upcoming Babylon (BABY) token listing. This event not only brings substantial rewards to users but also underscores MEXC's commitment to supporting the development of diverse ecosystems and projects across the cryptocurrency space.
High APR Opportunity Through BTC Fixed Saving Event
The BTC Fixed Saving Event, running from April 8 – May 9, 2025 (UTC), offers new users the opportunity to earn up to 99% APR on their BTC deposits. Event features include:
Babylon Airdrop+ Event with a Total Prize Pool of 150,000 USDT
In addition to the BTC Fixed Saving Event, MEXC is also hosting the Babylon (BABY) Airdrop+ Event, which runs from April 3 – April 24, 2025. Users can participate and share the prize pool in the following ways:
Benefit 1: New users can deposit to share 80,000 USDT in Futures bonuses.
Benefit 2: Trade in the Futures Challenge to share 50,000 USDT in Futures bonuses (open to all users).
Benefit 3: Invite new users and share 20,000 USDT in Futures bonuses (open to all users).
For full event details and participation rules, visit the BTC Fixed Saving Event page and Babylon Airdrop+ Event page.
MEXC's Commitment to User-Centric Innovation
In addition to the BTC Fixed Saving Event and the Babylon Airdrop+ Event, MEXC continues to prioritize the interests of its users. By offering high APR opportunities, 0 Trading Fee, and other user-centric services, MEXC demonstrates its commitment to delivering value and supporting its global user base.
Looking to the future, MEXC remains focused on upholding its mission of being the easiest way to crypto. The platform is committed to fostering industry development and reinforcing its advantages in fast token listings and a broad selection of trending tokens. According to the latest TokenInsight report, from November 1, 2024, to February 15, 2025, MEXC led the industry with an impressive 461 spot listings. Additionally, during the bi-weekly periods, MEXC maintained a high listing frequency, consistently ranking among the top six exchanges and demonstrating its ability to quickly capture market trends. Through these efforts, MEXC empowers global users to seize market opportunities and unlock greater investment potential.
About MEXC
Founded in 2018, MEXC is committed to being "Your Easiest Way to Crypto." Serving over 36 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC
Risk Disclaimer:
The information provided in this article regarding cryptocurrencies does not constitute investment advice. Given the highly volatile nature of the cryptocurrency market, investors are encouraged to carefully assess market fluctuations, the fundamentals of projects, and potential financial risks before making any trading decisions.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MEXC Launches Babylon (BABY) Exclusive BTC Fixed Saving Event with up to 99% APR
AUCKLAND, New Zealand, May 2, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence.
There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology.
AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing.
VLU's are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only ~40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur[1].
The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025.
The study compared 470 VLU's that had been treated with Endoform Natural to 360 VLU's that had been treated with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that 'real-world' use of both products could be compared.
"There is a growing awareness of RWE studies to validate clinical performance" says Chief Scientific Officer, Dr. Barnaby May. "These types of studies enable much larger patient numbers to be compared versus traditional randomized controlled trials. Given that RWE studies use data from 'real-world' use of a treatment, the results can be more meaningful, especially in wound care where there is a high degree of variability in how wounds are cared for and patient factors."
The study found that VLUs treated with Endoform Natural healed up to ~ 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment.
The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural.
Dr. Gregory Bohn MD was part of the research team. "I was first introduced to Endoform in 2012 and started using the product to treat my own patients with VLUs. This new data validates what I have seen in my own practice managing VLUs with Endoform."
This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituted collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural[2].
The study is available online here.
[1] Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72.
[2] Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comparative effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022 May;19(4):741-753.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.
